http://www.zibb.com/all/theme/cq/ImmunoGen+Incorporated Zibb. The Global business search engine. en-US search@zibb.com (RB Search)Copyright (c) 2007 Reed Business Information. All rights reserved.Tue, 04 Nov 2008 14:10:14 GMTTue, 04 Nov 2008 14:10:14 GMT608831http://www.zibb.com/all/theme/cq/ImmunoGen+Incorporated http://www.zibb.com/images/en/g_zibb_logo_beta.gif http://www.zibb.com/article/4303618/Video+Sector+Focus+BankingBanking Industry Recovery - Analysis and Discussion with Morgan Joseph Founder/Co-Head Frederick Joseph: Banks Need to De-Lever More http://www.clipsyndicate.com/video/playlist/1998/738145?cpt=8&wpid=523http://www.zibb.com/article/4303618/Video+Sector+Focus+BankingImmunoGen IncorporatedTue, 04 Nov 2008 14:10:14 GMThttp://www.immunogen.com/ImmunoGen, Inc. develops targeted anticancer therapeutics. Our proprietary Tumor-Activated Prodrug (TAP) technology and strong antibody expertise form the basis for our development of our own products as well as of our partnerships with other companies.http://www.immunogen.com/ImmunoGen Incorporatedhttp://www.intercontinental.net/News/News.asp?id=2&NewsID=98WALTHAM, MA-In one of the bigger coups for suburban Boston s life sciences sector, ImmunoGen Inc. is relocating here from East Cambridge, parties involved in the transaction have announced. The firm will occupy 89,000 sf of 830 Winter St.http://www.intercontinental.net/News/News.asp?id=2&NewsID=98ImmunoGen Incorporatedhttp://www.xconomy.com/boston/2008/01/29/immunogens-mitch-sayare-on-what-sustains-a-company-and-its-ceo-through-decades-of-starting-up/Call it the 27-year-old startup: ImmunoGen, one of biotech’s oldest companies, has yet to get a drug on the market more than a quarter century after its formation in 1981. This year may mark a long-awaited turning point for the Cambridge, MA-based company, though.http://www.xconomy.com/boston/2008/01/29/immunogens-mitch-sayare-on-what-sustains-a-company-and-its-ceo-through-decades-of-starting-up/ImmunoGen Incorporatedhttp://www.avigen.com/boardofdirectors.phpZola Horovitz, Ph.D., Chairman of the Board, has served as a director of Avigen since November 1994. Dr. Horovitz has been an independent consultant to pharmaceutical and biotechnology companies since May 1994. From 1991 to May 1994, Dr.http://www.avigen.com/boardofdirectors.phpImmunoGen Incorporatedhttp://www.newratings.com/headlines/ImmunoGen_US45253H1014.htmlCopyright © 2002 - 2008 newratings.com GmbH | Legal | Licensing Quote data provided by IS.eFinance Solutions (powered by IS.Teledata AG) using StandardPoor's ComStock Inc. and others. Delay times are 15 mins for European exchanges and NASDAQ, 20 mins for NYSE and AMEX.http://www.newratings.com/headlines/ImmunoGen_US45253H1014.htmlImmunoGen Incorporatedhttp://www.evaluatepharma.com/CoInfo/CoInfo-IMGN.htmEvaluatePharma provides historic and forecast sales from 1986 to 2010 for worldwide and US Rx (prescription drugs) and OTC drugs. EvaluatePharma analysts continuously update company models from SEC filings, annual reports, investor/analyst presentations, company press releases, FDA and USPTO.http://www.evaluatepharma.com/CoInfo/CoInfo-IMGN.htmImmunoGen Incorporatedhttp://www.processdevelopment.net/index.aspx?ID=66871Diosynth Biotechnology, Inc. has announced the execution of an agreement with ImmunoGen, Inc. for the production of antibody to be used in the manufacture of ImmunoGen's huN901-DM1 anticancer compound.http://www.processdevelopment.net/index.aspx?ID=66871ImmunoGen Incorporatedhttp://www.quotelinks.com/companies/imgn.htmlStock quotes, news and charts for ImmunoGen, Inc. Quotes Simple Charts Stock News MSN Investor Thomson Investors Short Interest Yahoo Finance CBS Marketwatch BigCharts StockCharts.com Yahoo Lycos Investing Quicken Yahoo News Quote.com (Lycos) CNET news ZDNet Business Week Stock earnings,http://www.quotelinks.com/companies/imgn.htmlImmunoGen Incorporatedhttp://www.pharmacychoice.com/News/article.cfm?Article_ID=37874Business Editors/Health Editors BIOWIRE2K CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 4, 2006--ImmunoGen, Inc. (Nasdaq: IMGN) today announced that sanofi-aventis has initiated clinical testing of AVE1642, a therapeutic antibody that binds to the Insulin-like Growth Factor 1 Receptor (IGF-1R).http://www.pharmacychoice.com/News/article.cfm?Article_ID=37874ImmunoGen Incorporatedhttp://www.bioexchange.com/news/news_page.cfm?id=21058IMGN News, a biotechnology company that develops targeted\r\nanticancer products, today announced that Centocor has licensed\r\ncertain exclusive rights to ImmunoGens TumorActivated Prodrug TAP\r\ntechnology.http://www.bioexchange.com/news/news_page.cfm?id=21058ImmunoGen Incorporatedhttp://stlouis.bizjournals.com/boston/gen/ImmunoGen_Inc_69A42B95174647298A312198A83E45D0.htmlOur forthcoming service has integrated three primary components into company profiles. Discovering relevant information about companies, qualifying it with sales trigger data and connecting you through our patented relationship mapping.http://stlouis.bizjournals.com/boston/gen/ImmunoGen_Inc_69A42B95174647298A312198A83E45D0.htmlImmunoGen Incorporatedhttp://www.fiercebiotech.com/story/immunogen-sweetens-deal-with-genentech/2006-05-05FierceBiotech is the biotech industry daily monitor, with a special focus on drug discovery and clinical trials. Keep up to speed with the latest biotechnology trends, breakthroughs and fda approval news.http://www.fiercebiotech.com/story/immunogen-sweetens-deal-with-genentech/2006-05-05ImmunoGen Incorporatedhttp://www.legalcasedocs.com/120/241/237.htmlconvertible debentures and common stock in 1995. Parnes, Herman and Knoll live in Brooklyn and Seitler lives in Monsey, New York. Neither Datek nor ImmunoGen, a Nasdaq-listed biopharmaceutical company based in Cambridge, Massachusetts, is charged with any wrongdoing.http://www.legalcasedocs.com/120/241/237.htmlImmunoGen Incorporatedhttp://www.bloomberg.com/apps/news?pid=conews&tkr=IMGN:USBloomberg Anywhere Software Support Live Support Feedback Bloomberg Bloomberg Anywhere Updated: New York, Apr 06 13:51 London, Apr 06 18:51 Tokyo, Apr 07 02:51 Search Symbol Lookup Home News Market Data Investment Tools TV and Radio About Bloomberg Careers Contact Us Tools Portfolio Tracker Markethttp://www.bloomberg.com/apps/news?pid=conews&tkr=IMGN:USImmunoGen Incorporatedhttp://www.investorideas.com/Research/Industries/BioArticles/ImmunoGen_Shares_Gain.aspImmunoGen Shares Gain Due To Second Genentech Licensing Deal LONDON April 28, 2005 - ImmunoGen, Inc. (IMGN) shares rose by 7.http://www.investorideas.com/Research/Industries/BioArticles/ImmunoGen_Shares_Gain.aspImmunoGen Incorporatedhttp://www.mintz.com/clients/detail/40/ImmunoGen_Inc/ImmunoGen develops innovative biopharmaceuticals for the treatment of cancer. The company's mission is to be the leader in the application of monoclonal antibodies for that treatment.http://www.mintz.com/clients/detail/40/ImmunoGen_Inc/ImmunoGen Incorporatedhttp://www.micromedex.com/pressroom/news_feeds/?story_ID=96134&category=16Get the news that matters to you. Create your own customized news service that delivers the latest information directly to you. Plus you can view the most current press releases from Micromedex.http://www.micromedex.com/pressroom/news_feeds/?story_ID=96134&category=16ImmunoGen Incorporatedhttp://waysandmeans.house.gov/legacy/fullcomm/107cong/4-17-02/4-17saya.htmStatement of Mitchel Sayare, Ph.D., President, Chief Executive Officer, and Chairman, ImmunoGen, Inc., Cambridge, Massachusetts, on behalf of the Biotechnology Industry Organizationhttp://waysandmeans.house.gov/legacy/fullcomm/107cong/4-17-02/4-17saya.htmImmunoGen Incorporatedhttp://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/09-06-2000/0001305338&EDATE=Multi-Product Collaboration to Combine ImmunoGen's Tumor-Activated Prodrug Technology With Abgenix's Fully Human Antibodies CAMBRIDGE, Mass. and FREMONT, Calif., Sept. 6 /PRNewswire/ -- ImmunoGen, Inc. (Nasdaq: IMGN) and Abgenix, Inc.http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/09-06-2000/0001305338&EDATE=ImmunoGen Incorporatedhttp://www.gene.com/gene/news/press-releases/display.do?method=detail&id=4614CAMBRIDGE, Mass. and SOUTH SAN FRANCISCO, Calif., May 8, 2000 -- ImmunoGen, Inc. (Nasdaq: IMGN) and Genentech, Inc. (NYSE: DNA) today announced a second collaboration between the two companies.http://www.gene.com/gene/news/press-releases/display.do?method=detail&id=4614ImmunoGen Incorporatedhttp://www.biotest.de/ww/en/pub/folder_ag/news/11_07_2006_biotest_secures_exc.htmCollaboration and licensing agreement with ImmunoGen secures future global sales of cancer therapy based on the BT-062 antibody. Option for joint development in the USA – license payments dependent on milestones Cambridge, MA/Dreieich, July 11, 2006.http://www.biotest.de/ww/en/pub/folder_ag/news/11_07_2006_biotest_secures_exc.htmImmunoGen Incorporatedhttp://www.holdrs.com/holdrs/main/index.asp?Action=Headlines&Description=&Image=&symb=IMGNCopyright © 2008 MarketWatch, Inc. All rights reserved. Please see our Terms of Use. MarketWatch, the MarketWatch logo, and BigCharts are registered trademarks of MarketWatch, Inc. Intraday data provided by Interactive Data Real-Time Services and subject to the Terms of Use.http://www.holdrs.com/holdrs/main/index.asp?Action=Headlines&Description=&Image=&symb=IMGNImmunoGen Incorporatedhttp://www.immunogen.com/wt/home/theurl-> Home -> Contact Us -> Site Map -> Search ImmunoGen, Inc. Company Overview Our TAP Technology Product Pipeline Investor Information Join Our Team 404 Page Not Found 404 Page Not Found © 2008 ImmunoGen, Inc. | Privacy Policy | Usage Policy Last updated July 7, 2005http://www.immunogen.com/wt/home/theurlImmunoGen Incorporatedhttp://www.pharmacychoice.com/News/article.cfm?Article_ID=21261"We are delighted to announce this milestone in our collaboration with Genentech," said Mitchel Sayare, Chairman and CEO. "Genentech was the first company to license rights to our TAP technology and has evaluated it extensively.http://www.pharmacychoice.com/News/article.cfm?Article_ID=21261ImmunoGen Incorporated